RT Journal Article SR Electronic T1 Bisphosphonate-Associated Atypical Subtrochanteric Femur Fracture JF Journal of Nuclear Medicine Technology JO J. Nucl. Med. Technol. FD Society of Nuclear Medicine SP 72 OP 73 DO 10.2967/jnmt.114.139923 VO 43 IS 1 A1 Ely A. Wolin A1 Kevin P. Banks A1 Penny J. Vroman YR 2015 UL http://tech.snmjournals.org/content/43/1/72.abstract AB Bisphosphonates help prevent progressive bone mineralization loss and subsequent osteoporotic fractures. However, long-term bisphosphonate therapy paradoxically increases the risk of a unique injury called an atypical subtrochanteric femur fracture. Despite this, the benefits of bisphosphonates outweigh the risks, because far more pathologic fractures are prevented than induced. The early identification of atypical subtrochanteric femur fractures is important as there is high associated morbidity and mortality. We describe a case of a 76-y-old woman with a completed bisphosphonate-associated atypical subtrochanteric femur fracture.